You don't even need to research - though one should. Easy just to use his own examples. Yescarta makes Gilead around $1.5 billion a year. Kymriah makes Novartis around $0.5 billion. Breyanzi makes Bristol Myers Squibb around $1 billion.
That's just the three he mentioned, with a 60-65% failure rate....hmmm, that's $1.8-1.95 billion potential equivalence on simply those three's failure rates.
Its not a niche market at all. Let alone all the other application potential. Hence TPG happily took up a $275 million USD partnership with Precision in non-oncology applications - but then again that's a silly mkt cap too. The markets (ergo investors en masses) are too slow on the value in this stuff - opportunity for more informed buyers down here.
But indeed to your point, the costs of a full treatment regime in Yescarta, Breyanzi, etc are about $400K USD!!
IMU Price at posting:
4.2¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)